
A late-stage trial of GlaxoSmithKline’s investigational Crohn’s disease drug failed to benefit patients. The SHIELD-1 study was investigating vercirnon – …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

